|Page (1) of 1 - 06/19/12||email article||print page|
New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines(June 19, 2012)
New York, NY (PRWEB) June 19, 2012
A new syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases has been released by Medmeme, LLC., a global leader in comprehensive, integrated medical and science information database platforms. The report details the trends and potential for drug developers in immune/inflammatory diseases particularly focusing on three key disease indications: RA (rheumatoid arthritis), IBD (inflammatory bowel disease), and SLE (systemic lupus erythematosus). According to the Centers for Disease Control and Prevention (CDC) and the Arthritis Foundation (AF), between 1.3 million and 1.5 million people in the United States have RA. The CDC also reports than mortality rates among RA patients are nearly 2.5 times higher than those in the general population, owing primarily to excess risk of cardiovascular disease, infections, and some cancers. The Medmeme report illustrates that treatment of these three indications commands much of the R&D effort and market in this therapeutic category and represents recent, notable scientific progress. R&D for the three indications also offers a window into issues that are relevant broadly across the category.
Medmeme CEO Mahesh Naithani describes the marketplace: The value of the immune/inflammatory disease pharmaceutical markets has been driven by very intense research to characterize pathological factors, which was then translated into development of highly targeted biological therapies. Commercial success has come to the companies and brands that have contributed to this clinical revolution. Just three drugs in this therapeutic area Amgen/Pfizers Enbrel, Johnson & Johnsons Remicade, and Abbotts Humira respectively were the seventh, eighth, and ninth highest selling pharmaceutical brands worldwide in 2010, with combined sales exceeding $18 billion. Need for new treatments and market potential have encouraged many companies to be active such as Roche, Merck, Biogen Idec, AstraZeneca, Eli Lilly, Novartis, Regeneron, GlaxoSmithKline, Astellas, and Sanofi, others too. Another major driver of success in immune/inflammatory disease markets has been company strategies of label expansion into multiple disease areas, particularly for biologics like the TNF- inhibitors.
Scientific data from the Medmeme database shows that discussion centering on late-stage RA emerging therapies in medical conference presentations and journal publications increased in 2011. This increase is primarily attributable to novel non-TNF-alpha target drugs such as: AstraZenecas fostamatinib, an oral Syk kinase inhibitor, Novartiss secukinumab, a monoclonal antibody against IL-17A, and Pfizers tofacitinib, an oral JAK inhibitor. Of these three frontrunner emerging therapies, Pfizers tofacitinib may reach market this year. The drug was submitted for U.S. approval to treat RA at the end of 2011.
The syndicated TrendsmemeTM Report: Immune and Inflammatory Diseases can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports.
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595
Read the full story at http://www.prweb.com/releases/2012/6/prweb9616233.htm.
Related Keywords:medical procedure/test, medical research, medical staff, medical specialisation, medical service, medical conditions, fishing industry, healthcare provider, cinema industry, radio industry, television industry, music industry, process industry, healthcare policy, health and beauty product, health, health treatment, health organisations, government health care, private health care, , health and safety at work, lifestyle and leisure, lifestyle (house and home), health insurance, inorganic chemical, organic chemical, biological and chemical weapons,